Published in Curr Opin Lipidol on August 01, 2001
Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest (2004) 3.63
Coronary endothelial dysfunction in patients with early coronary artery disease is associated with the increase in intravascular lipid core plaque. Eur Heart J (2013) 1.59
CTP synthase 1, a smooth muscle-sensitive therapeutic target for effective vascular repair. Arterioscler Thromb Vasc Biol (2013) 1.45
Haplotype-specific effects on endothelial NO synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler Thromb Vasc Biol (2002) 1.40
Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc (2009) 1.38
In vivo interrogation of the molecular display of atherosclerotic lesion surfaces. Am J Pathol (2003) 1.13
Relation between C reactive protein concentrations and coronary microvascular endothelial function. Heart (2004) 1.08
The atheroprotective properties of Hsp70: a role for Hsp70-endothelial interactions? Cell Stress Chaperones (2009) 1.08
Cytomegalovirus-induced effector T cells cause endothelial cell damage. Clin Vaccine Immunol (2012) 1.02
Endothelial dysfunction in diabetes mellitus: possible involvement of endoplasmic reticulum stress? Exp Diabetes Res (2012) 1.02
Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional. J Biol Chem (2014) 0.98
p53 impairs endothelial function by transcriptionally repressing Kruppel-Like Factor 2. Arterioscler Thromb Vasc Biol (2010) 0.93
Regulation of peripheral blood flow in complex regional pain syndrome: clinical implication for symptomatic relief and pain management. BMC Musculoskelet Disord (2009) 0.91
Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches. J Korean Med Sci (2015) 0.91
Evaluation of bioavailability of nitric oxide in coronary circulation by direct measurement of plasma nitric oxide concentration. Proc Natl Acad Sci U S A (2005) 0.89
Positron emission tomography imaging of atherosclerosis. Theranostics (2013) 0.87
The role of oxysterols in control of endothelial stiffness. J Lipid Res (2012) 0.87
Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview. Curr Med Chem (2009) 0.86
Zc3h12c inhibits vascular inflammation by repressing NF-κB activation and pro-inflammatory gene expression in endothelial cells. Biochem J (2013) 0.85
Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol. Cytometry A (2009) 0.84
2-(2,4-dihydroxyphenyl)-5-(E)-propenylbenzofuran promotes endothelial nitric oxide synthase activity in human endothelial cells. Biochem Pharmacol (2012) 0.83
Reduced nitrate level in individuals with hypertension and diabetes. J Cardiovasc Dis Res (2011) 0.83
Histone deacetylase 5 interacts with Krüppel-like factor 2 and inhibits its transcriptional activity in endothelium. Cardiovasc Res (2014) 0.83
Association of coronary artery disease, erectile dysfunction, and endothelial nitric oxide synthase polymorphisms. Heart Vessels (2009) 0.80
Antiobesity and vasoprotective effects of resveratrol in apoE-deficient mice. J Med Food (2014) 0.79
Coagulation and the vessel wall in pulmonary embolism. Pulm Circ (2013) 0.79
Pathogenesis of diabetic cerebral vascular disease complication. World J Diabetes (2015) 0.78
Procyanidin C1 causes vasorelaxation through activation of the endothelial NO/cGMP pathway in thoracic aortic rings. J Med Food (2014) 0.78
Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes. J Matern Fetal Neonatal Med (2014) 0.78
The spectral analysis of photoplethysmography to evaluate an independent cardiovascular risk factor. Int J Gen Med (2014) 0.78
Chemerin as an independent predictor of cardiovascular event risk. Ther Adv Endocrinol Metab (2016) 0.77
Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod. Drug Des Devel Ther (2015) 0.77
The effect of simvastatin treatment on endothelial cell response to shear stress and tumor necrosis factor alpha stimulation. Biomed Eng Online (2015) 0.77
Identification and characterization of [6]-shogaol from ginger as inhibitor of vascular smooth muscle cell proliferation. Mol Nutr Food Res (2015) 0.77
Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention. J Intern Med (2015) 0.76
Pretreatment with β-Boswellic Acid Improves Blood Stasis Induced Endothelial Dysfunction: Role of eNOS Activation. Sci Rep (2015) 0.76
Low serum insulin-like growth factor-1 in patients with erectile dysfunction. Basic Clin Androl (2016) 0.75
Histone deacetylases and cardiovascular cell lineage commitment. World J Stem Cells (2015) 0.75
Adiporedoxin suppresses endothelial activation via inhibiting MAPK and NF-κB signaling. Sci Rep (2016) 0.75
Serum Homocysteine Concentration Is Significantly Associated with Inflammatory/Immune Factors. PLoS One (2015) 0.75
Insulin resistance and vessel endothelial function. J R Soc Med (2002) 0.75
Susceptible gene of stasis-stagnation constitution from genome-wide association study related to cardiovascular disturbance and possible regulated traditional Chinese medicine. BMC Complement Altern Med (2015) 0.75
Association of worsening arterial stiffness with incident heart failure in asymptomatic patients with cardiovascular risk factors. Hypertens Res (2016) 0.75
Clopidogrel Improves Skin Microcirculatory Endothelial Function in Persons With Heightened Platelet Aggregation. J Am Heart Assoc (2016) 0.75
Endothelial Dysfunction Markers in Low Cardiovascular Risk Individuals: Comparison of Males and Females. J Med Biochem (2017) 0.75
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 9.16
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell (1998) 7.46
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest (1994) 7.25
PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell (1989) 6.26
Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med (1986) 6.05
Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol (1995) 5.26
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest (1995) 5.09
Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest (2000) 4.79
Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol (1987) 3.61
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med (1995) 3.60
Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation (2001) 3.47
Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol (1986) 3.35
Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature (1998) 3.31
Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation (1990) 3.20
Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest (1998) 3.17
Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol (1998) 3.04
An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb (1993) 2.77
The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci (2001) 2.75
The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med (1991) 2.74
Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation (1999) 2.73
Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension (2001) 2.69
Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol (2001) 2.63
Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation (1998) 2.63
Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A (1997) 2.56
Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol (1995) 2.54
Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation (2001) 2.53
Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol (2000) 2.50
Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res (1994) 2.46
Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med (2001) 2.42
Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res (1998) 2.39
Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol (1989) 2.39
ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol (1999) 2.37
Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation (1999) 2.33
Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest (1973) 2.28
Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation (2000) 2.25
Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest (1986) 2.21
Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol (1992) 2.19
Precordial S-T segment elevation mapping: an atraumatic method for assessing alterations in the extent of myocardial ischemic injury. The effects of pharmacologic and hemodynamic interventions. Am J Cardiol (1972) 2.19
Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest (1999) 2.16
Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest (1999) 2.13
Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation (1997) 2.12
Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem (1995) 2.11
Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation (1998) 2.11
Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation (1972) 2.10
Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol (1996) 2.09
An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation (2001) 2.09
A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Catheter Cardiovasc Interv (2001) 2.08
Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol (1990) 2.07
Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation (1997) 2.07
PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol (1999) 2.07
Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide. Am J Physiol (1996) 2.06
The unstable atheroma. Arterioscler Thromb Vasc Biol (1997) 2.05
Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb (1991) 2.04
Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. J Cell Physiol (1983) 2.03
Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest (1999) 2.03
Nonclassical hydrophobic effect in membrane binding equilibria. Biochemistry (1991) 2.02
PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation (1999) 2.02
Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol (1999) 2.00
Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A (1995) 2.00
Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms. Circulation (1999) 1.97
CD40 signaling and plaque instability. Circ Res (2001) 1.97
Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat Med (2001) 1.96
Leupeptin, a protease inhibitor, decreases protein degradation in normal and diseased muscles. Science (1978) 1.93
Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation (1999) 1.87
Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (1999) 1.86
Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest (1972) 1.86
Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest (1996) 1.86
Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol (1991) 1.82
Fatty acid modulation of endothelial activation. Am J Clin Nutr (2000) 1.81
Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells. J Immunol (1987) 1.79
Inflammation and thrombosis: the clot thickens. Circulation (2001) 1.79
Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest (1997) 1.77
Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor- deficient mice. J Clin Invest (1998) 1.76
Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation (1999) 1.74
Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler Thromb Vasc Biol (1996) 1.71
Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation (1988) 1.69
Novel inflammatory markers of coronary risk: theory versus practice. Circulation (1999) 1.65
Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk (2001) 1.65
Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol (1997) 1.65
Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate. Circulation (1990) 1.64
Inducible expression of class II major histocompatibility complex antigens and the immunogenicity of vascular endothelium. Transplantation (1986) 1.64
Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A (2000) 1.63
Induced expression of endothelial-leukocyte adhesion molecules in human cardiac allografts. Transplantation (1991) 1.62
Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells. J Exp Med (1987) 1.61
The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res (2000) 1.60
Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am J Pathol (1993) 1.58
Hyperlipidemia and atherosclerotic lesion development in LDL receptor-deficient mice fed defined semipurified diets with and without cholate. Arterioscler Thromb Vasc Biol (1999) 1.57
Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb (1991) 1.57
HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol (2000) 1.56
Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol (1998) 1.55
Implantation of vascular grafts lined with genetically modified endothelial cells. Science (1989) 1.54
Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun (1990) 1.54
Mechanical strain tightly controls fibroblast growth factor-2 release from cultured human vascular smooth muscle cells. Circ Res (1997) 1.54
Soluble CD40L and cardiovascular risk in women. Circulation (2001) 1.52
Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation (1989) 1.52
Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res (2003) 1.51
The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells. J Exp Med (2000) 1.50
Reduction by hyaluronidase of myocardial necrosis following coronary artery occlusion. Circulation (1972) 1.50
Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol (2000) 1.49